Longeveron Set to Present at the Emerging Growth Virtual Conference
MIAMI -- Longeveron Inc. (NASDAQ: LGVN), a pioneering clinical stage regenerative medicine biotechnology firm, is gearing up for its participation in the Emerging Growth Virtual Conference. This event is scheduled for December 4-5, 2024, and represents a significant opportunity for the company to showcase its groundbreaking innovations in cellular therapies aimed at life-threatening and chronic aging-related conditions.
Presentation Details and What to Expect
Longeveron's presentation will take place on December 5, 2024, from 12:00 to 12:30 p.m. ET. Industry professionals and interested parties can access the presentation through the company's dedicated “Events and Presentations” section on its website. Attendees will have the opportunity to engage with the presentation and ask questions either in advance or during the live event.
Webcast Information
After the conference, a replay of the webcast will be available on the Longeveron website for 180 days, allowing shareholders and stakeholders to access the content at their convenience. This reaffirms Longeveron’s commitment to transparency and accessibility for its investors and the broader community.
About Longeveron Inc.
Longeveron specializes in developing regenerative medicines addressing unmet medical needs through innovative biotechnology. Its flagship product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from healthy adult donors' bone marrow. This unique therapy showcases a variety of potential mechanisms, demonstrating properties that are pro-vascular, anti-inflammatory, and instrumental in tissue repair and healing.
Pipeline and Regulatory Designations
The company is currently focusing on three main indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and age-related frailty. Lomecel-B™ has garnered extensive recognition from regulatory agencies, receiving key FDA designations for its developmental programs, including Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) status, which highlight its potential to transform treatment in these critical areas.
Company Vision and Future Directions
Longeveron aims to leverage its capabilities to further advance its product offerings and expand its clinical trials, thereby improving the lives of patients with chronic conditions. With its cutting-edge research and development strategies, the company is well-positioned to make significant advancements in the biotechnology sector.
Contact Information
For any inquiries or additional information regarding investor relations, please reach out to Derek Cole at Investor Relations Advisory Solutions via email at derek.cole@iradvisory.com. The company encourages open communication with its stakeholders as they continue on their path of growth and innovation.
Frequently Asked Questions
What is Longeveron Inc. known for?
Longeveron Inc. is known for developing innovative cellular therapies for life-threatening and chronic aging-related conditions.
When will Longeveron present at the Emerging Growth Conference?
Longeveron will present on December 5, 2024, from 12:00 to 12:30 p.m. ET.
How can I access the conference presentation?
The conference presentation can be accessed through the “Events and Presentations” section on Longeveron’s website.
What is Lomecel-B™?
Lomecel-B™ is an allogeneic medicinal signaling cell therapy designed to address various medical needs, including hypoplastic left heart syndrome and Alzheimer’s disease.
What regulatory designations has Longeveron received?
Longeveron has received several FDA designations, including Orphan Drug, Fast Track, and RMAT designations for Lomecel-B™.
